March 23, 2021, Miami — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into a Material Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention (“CDC”) to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection. [Read more…]
Organicell Regenerative Medicine (OTCBB: BPSR), a clinical-stage biopharma company developing exosome-based regenerative therapies, has announced the release of a Case Report in the peer reviewed journal Frontiers in Medicine. This case study highlights the therapeutic potential of Organicell’s proprietary therapeutic, Zofin™, and its continued success as a drug candidate. [Read more…]
Although long overlooked, exosomes have been gaining momentum due to their potential for use as cell-free therapeutics. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. [Read more…]
French biotech company Ciloa wins the 2020 “Sanofi iTech Awards”.
The winning project is based on the unique innovation developed by Ciloa, which uses its customized exosomes for therapeutic purposes.
The “Sanofi iTech Awards” program funds and supports projects related to the development of innovative technologies in Healthcare that may lead to a subsequent research collaboration between Sanofi and Ciloa.
Exosome research is on the rise, fueled by an increasing recognition of the central role that exosomes play in intercellular (cell-to-cell) communication and transportation. As intracellular messengers, exosomes have the potential to mediate many of the therapeutics effects commonly associated with cells, with far fewer risks.
In this article:
- Exosome Research by Dr. Gabrielsson
- Unicyte AG on Exosomes Therapy
- Leading Exosome Research Journals
For competitors within the exosome marketplace, it is vital to assess existing and future trends. One of the best tools for assessing scientific progress is to review rates of exosome research.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and Chinese authors take second place.
When the term “exosome” is searched within scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author, with 37 articles, making her one of the global authorities on exosome research. A full list of Dr. Gabrielsson’s exosome publications can be viewed at this link.
When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Prof. Giovanni Camussi. The company is also a market leader in terms of patents and translational programs.
Leading Exosome Journals
Interestingly, two scientific journals have been particularly favorable toward exosome publications, publishing the greatest quantity to date:
PloS ONE, a peer-reviewed open access scientific journal published by the Public Library of Science, has published 349 articles with the term “exosome” or “exosomes” in the title. A full list of the articles can be viewed here.
Journal of Biological Chemistry
The Journal of Biological Chemistry, a weekly peer-reviewed scientific journal published by the American Society for Biochemistry and Molecular Biology, has published 167 articles with the term “exosome” or “exosomes” in the title. A full list of the articles can be viewed here.
Google Trend data also shows a clear linear increase in interest in exosome-related topics. To compete for dominance within this market, it is essential to identify trends as they begin to impact the marketplace, not after they are in full effect.
If you found this blog valuable, subscribe to BioInformant’s stem cell industry updates.